肝がん患者の治療における陽子または光子による放射線療法
肝細胞癌に対する陽子対光子の第 III 相ランダム化試験
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To determine if overall survival (OS) is different for hepatocellular carcinoma patients treated with protons compared to photons.
SECONDARY OBJECTIVES:
I. To determine the difference in progression-free-survival (PFS) in patients with hepatocellular carcinoma (HCC) treated with protons compared to patients with HCC treated with photons.
II. To determine the difference in local progression (LP) in patients with HCC treated with protons compared to patients with HCC treated with photons.
III. To determine differences in toxicity in patients with HCC treated with protons versus photons.
IV. To determine differences in fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue in patients with HCC treated with protons, versus photons; as well as quality-adjusted survival, if the primary endpoint is met.
V. To determine if there are correlations between the baseline values of hepatocyte growth factor (HGF) and outcomes (OS/PFS/fatigue).
EXPLORATORY OBJECTIVES:
I. To determine differences in overall quality of life, measured by Functional Assessment of Cancer Therapy-Hepatobiliary Cancer (FACT-Hep) in patients with HCC treated with protons.
II. Biospecimen collection for future correlative science projects.
OUTLINE: Patients are randomized to 1 of 2 arms, photon or proton therapy (see Arms and Interventions).
Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI) and blood sample collection throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then yearly thereafter.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital Midtown
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、アメリカ、30342
- Emory Saint Joseph's Hospital
-
Atlanta、Georgia、アメリカ、30308
- Emory Proton Therapy Center
-
-
Illinois
-
Warrenville、Illinois、アメリカ、60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore、Maryland、アメリカ、21201
- Maryland Proton Treatment Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Dearborn、Michigan、アメリカ、48124
- Corewell Health Dearborn Hospital
-
Royal Oak、Michigan、アメリカ、48073
- Corewell Health William Beaumont University Hospital
-
Troy、Michigan、アメリカ、48085
- Corewell Health Beaumont Troy Hospital
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown、New Jersey、アメリカ、07748
- Memorial Sloan Kettering Monmouth
-
Montvale、New Jersey、アメリカ、07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack、New York、アメリカ、11725
- Memorial Sloan Kettering Commack
-
East White Plains、New York、アメリカ、10604
- Memorial Sloan Kettering Westchester
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10035
- New York Proton Center
-
Uniondale、New York、アメリカ、11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
West Chester、Ohio、アメリカ、45069
- University of Cincinnati Cancer Center-West Chester
-
-
Texas
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- University of Washington Medical Center - Montlake
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Pathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registration
-
Appropriate stage for study entry based on the following diagnostic workup:
- All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted
- Participants must have measurable disease at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 2 cm with conventional techniques or as > 1 cm with spiral CT scan
- Patient must have 3 or fewer single or multinodular tumors; for patients with a single lesion, lesion must be 15 cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than 10 cm in greatest dimension; for patients with three lesions, no lesion may be greater than 6 cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >= 1 cm and =< 15 cm in greatest dimension is allowed
-
Age >= 18
-
Zubrod performance status 0-1 within 30 days prior to registration
-
Negative urine or serum pregnancy test for women of childbearing potential within 7 days prior to study entry
-
Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
-
Platelets >= 50,000 cells/mm^3
-
Hemoglobin >= 9.0 g/dl; (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable)
-
Total bilirubin < 4 x institutional upper limit of normal (ULN)
-
Transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) < 6 x institutional ULN
-
Albumin >= 2.5 g/dl
-
Creatinine < 2 mg/dl
-
Prior chemotherapy, targeted biological therapy (e.g. sorafenib), surgery, transarterial chemoembolization (TACE), ablation for present disease is acceptable
-
Must have Child-Turcotte-Pugh (CTP) A or B7
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study registration
Exclusion Criteria:
- PRIOR TO STEP ONE REGISTRATION:
- Definitive clinical or radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > 3.0 cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph node or two 2 cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm
- Uncontrolled prior invasive malignancy, excluding the current diagnosis
- Systemic chemotherapy for the study cancer < 2 weeks prior to registration
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
- HIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 (cluster of differentiation 4)count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90)
- Prior liver transplant
- PRIOR TO STEP TWO RANDOMIZATION:
- Unable to obtain confirmation of payment coverage (insurance or other) for either possible treatment
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Proton Therapy (Arm 1)
Proton therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician. |
Fractions
他の名前：
|
|
実験的：Photon Therapy (Arm 2)
Photon therapy delivered in 5 fractions over 15 days or 15 fractions over 24 days, determined by the treating physician. |
Fractions
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Alive (Overall Survival)
時間枠：From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
|
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. |
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Alive Without Progression (Progression-free Survival)
時間枠：From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
|
Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. |
From randomization to progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
|
|
Percentage of Participants With Local Progression
時間枠：From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
|
Local progression rates are estimated using the cumulative incidence method in which death is treated as competing risk and participants alive without local failure are censored at last known follow-up. |
From randomization to local progression, death, or last follow-up, whichever occurs first. Median follow-up time for all patients at time of analysis was 20.4 months. One- and two-year estimates are reported.
|
|
Percentage of Participants With Grade 3+ Treatment-Related Adverse Events
時間枠：From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events. |
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months.
|
|
Change From Baseline to One Month in the Patient Reported Outcomes Measurement Information System - Fatigue Short Form version1.0 8a [PROMIS Fatigue Score]
時間枠：Baseline and one month
|
The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. |
Baseline and one month
|
|
Quality-adjusted LIfe Years
時間枠：Baseline up to 12 months
|
Was to be calculated using the EuroQol 5-Dimension Three Level Questionnaire (EQ-5D-3L). |
Baseline up to 12 months
|
|
Percentage of Participants Alive (Overall Survival) by Plasma Hepatocyte Growth Factor (HGF) Level
時間枠：From randomization to death or last follow-up. One- and two-year estimates will be reported.
|
Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at last known follow-up. HGF will be dichotomized at 2311 pg/mL. |
From randomization to death or last follow-up. One- and two-year estimates will be reported.
|
|
Percentage of Participants Alive Without Progression (Progression-free Survival) by HGF Level
時間枠：From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.
|
Progression is defined as local, regional, or distant progression. Progression-free survival rates are estimated using the Kaplan-Meier method, censoring participants alive without progression at time of last follow-up. HGF will be dichotomized at 2311 pg/mL. |
From randomization to progression, death, or last follow-up, whichever occurs first. One- and two-year estimates will be reported.
|
|
Change From Baseline to One Month in PROMIS Fatigue Score by HGF Level
時間枠：Baseline and one month
|
The PROMIS Fatigue Short Form v1.0 8a contains 8 items that assess self-reported fatigue symptoms over the past 7 days. Item responses are summed to obtain a raw score ranging from 8 to 40, which is then converted to a standardized T-score (mean = 50, standard deviation = 10). Higher T-scores indicate greater fatigue. Change from baseline is calculated as the post-baseline T-score minus the baseline T-score, with positive change scores indicating increased fatigue and negative change scores indicating decreased fatigue. HGF will be dichotomized at 2311 pg/mL. |
Baseline and one month
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Quality of Life by Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) Version 4
時間枠：Baseline up to 12 months
|
Differences between treatment arms in the overall score, the four domains (physical, social, emotional, and functional well-being), and the additional concerns subscale will also be analyzed. |
Baseline up to 12 months
|
|
Title: Percentage of Participants Alive (Overall Survival) by Sex
時間枠：From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
|
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to death or last follow-up. Median follow-up for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
|
|
Percentage of Participants Alive (Overall Survival) by Race
時間枠：From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
|
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
|
|
Percentage of Participants Alive (Overall Survival) by Ethnicity
時間枠：From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
|
NIH-required analysis. Survival rates are estimated using the Kaplan-Meier method, censoring participants alive at time of analysis. |
From randomization to death or last follow-up. Median follow-up time for all patients at time of analysis was 20.4 months. Two-year estimates are reported.
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NRG-GI003
- U10CA180868 (米国 NIH グラント/契約)
- NRG-GI003 (その他の識別子：CTEP)
- NCI-2016-02009 (レジストリ識別子：CTRP (Clinical Trial Reporting Program))
- NRG-GI003 (その他の識別子：NRG Oncology)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。